Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
- All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned - - Consortium of U.S. academic sites planning to commence investigator-initiated studies in parallel -- Evaluating a Phase 2/3 clinical development program pending regulatory feedback and data from treatment experiences - HAMILTON, Bermuda, March 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced early evidence of treatment response with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRa), in a treatment protocol in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation. The t
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent PericarditisGlobeNewswire
- Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis InitiativeGlobeNewswire
- New initiative aims to help tens of thousands with recurrent pericarditis [Yahoo! Finance]Yahoo! Finance
KNSA
Earnings
- 4/23/24 - Miss
KNSA
Sec Filings
- 6/25/24 - Form 8-K
- 6/14/24 - Form 8-K
- 6/7/24 - Form 4
- KNSA's page on the SEC website